Finance

Lists
Q3 2026 earnings • released • EPS beat +7.92% • Revenue beat +1.34%
See results
AZN:NYSE
AstraZeneca PLC (US)
$186.58
-0.10%
(-0.18) 1D
$187.50
+0.49% (+0.92)
After hours
Closed: Nov 2, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AZN...
Open
$184.59
High
$187.94
Low
$184.52
Mkt. cap
289.50B
Avg. vol.
2.95M
Volume
2.70M
Dividend
1.73%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
26.40
52-wk high
$212.71
52-wk low
$80.48
EPS
$7.07
Beta
0.30
Shares outstanding
1.55B
No. of employees
96K
Open
$184.59
High
$187.94
Low
$184.52
Mkt. cap
289.50B
Avg. vol.
2.95M
Volume
2.70M
Dividend
1.73%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
26.40
52-wk high
$212.71
52-wk low
$80.48
EPS
$7.07
Beta
0.30
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com
Analyst
Recommendation
Action
Price target
Projected
Date
No analyst ratings found.
Last report
Oct 30, 2026
Fiscal period
Q3 2026
$2.79 / $2.59
+7.92%beat
Revenue / Est. (USD)
16.21B / 16.00B
+1.34%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
15.50B
15.29B
15.38B
16.21B
Cost of goods sold
3.17B
2.67B
2.53B
2.93B
Cost of revenue
3.17B
2.67B
2.53B
2.93B
Research and development expenses
3.62B
3.47B
3.67B
3.66B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.32B
5.03B
5.72B
5.11B
Operating expense
8.99B
8.34B
9.24B
8.49B
Total operating expenses
12.16B
11.02B
11.78B
11.42B
Operating income
3.35B
4.27B
3.61B
4.79B
Other non operating income
-247.00M
-
-
-
EBT including unusual items
2.63B
3.91B
2.80B
3.96B
EBT excluding unusual items
3.05B
3.94B
3.24B
4.36B
Income tax expense
300.00M
833.00M
291.00M
842.00M
Effective tax rate
11.41%
21.28%
10.40%
21.27%
Other operating expenses
53.00M
-155.00M
-152.00M
-276.00M
Net income
2.33B
3.08B
2.51B
3.12B
Net profit margin
15.00%
20.15%
16.30%
19.23%
Earnings per share
2.12
1.29
2.63
2.79
Interest and investment income
135.00M
73.00M
80.00M
67.00M
Interest expense
-155.00M
-393.00M
-435.00M
-477.00M
Net interest expenses
-20.00M
-320.00M
-355.00M
-410.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.11B
5.64B
5.19B
6.26B
Gain or loss from assets sale
-37.00M
-34.00M
-94.00M
-28.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps